Abstract
The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem.
| Original language | English |
|---|---|
| Article number | 103243 |
| Journal | eClinicalMedicine |
| Volume | 84 |
| DOIs | |
| State | Published - Jun 2025 |
Bibliographical note
Publisher Copyright:© 2025 The Author(s)
Keywords
- Digital rheumatology
- Digital therapeutics
- Explainable AI models
- Novel digital biomarkers
- Psoriatic arthritis
- iPROLEPSIS European research initiative
Fingerprint
Dive into the research topics of 'European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver